Abstract:Hypertension poses a significant burden in the general population, being responsible for increasing cardiovascular morbidity and mortality, leading to adverse outcomes. Moreover, the association of hypertension with dyslipidaemia, obesity, and insulin resistance, also known as metabolic syndrome, further increases the overall cardiovascular risk of an individual. The complex pathophysiological overlap between the components of the metabolic syndrome may in part explain how novel antidiabetic drugs express pleiotropic effects. Taking into consideration that a significant proportion of patients do not achieve target blood pressure values or glucose levels, more efforts need to be undertaken to increase awareness among patients and physicians. Novel drugs, such as incretin-based therapies and renal glucose reuptake inhibitors, show promising results in decreasing cardiovascular events in patients with metabolic syndrome. The effects of sodium-glucose co-transporter-2 inhibitors are expressed at different levels, including renoprotection through glucosuria, natriuresis and decreased intraglomerular pressure, metabolic effects such as enhanced insulin sensitivity, cardiac protection through decreased myocardial oxidative stress and, to a lesser extent, decreased blood pressure values. These pleiotropic effects are also observed after treatment with glucagon-like peptide-1 receptor agonists, positively influencing the cardiovascular outcomes of patients with metabolic syndrome. The initial combination of the two classes may be the best choice in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors because of their complementary mechanisms of action. In addition, the novel mineralocorticoid receptor antagonists show significant cardio-renal benefits, as well as anti-inflammatory and anti-fibrotic effects. Overall, the key to better control of hypertension in patients with metabolic syndrome is to consider targeting multiple pathogenic mechanisms, using a combination of the different therapeutic agents, as well as drastic lifestyle changes. This article will briefly summarize the association of hypertension with metabolic syndrome, as well as take into account the influence of antidiabetic drugs on blood pressure control.

[Pathophysiologic basis of arterial hypertension in diabetic patients]

[Basal and reactive renin and aldosterone secretion in arterial hypertension of insulin dependent diabetics]

[Principles of hypotension treatment in patients with diabetes]

Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease

Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes

Experimental and Clinical Evidence of Altered Interactions in Obesity and Diabetes Mellitus

Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs

Common metabolic features of hypertension and type 2 diabetes

Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease

Hypertension in diabetes care: emerging roles of recent hypoglycemic agents

Dietary approach for the treatment of arterial hypertension in patients with diabetes mellitus

Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms

Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension

MEDICAL BASIS OF DIABETIC NEUROPATHY FORMATION (REVIEW)

Novel Insights in the Hypertension Treatment & Type 2 Diabetics Induced by Angiotensin Receptor Blockers: MD Simulation Studies & Molecular Docking of Some Promising Natural Therapies

Angiotensin II-Superoxide Signaling and Arterial Baroreceptor Function in Type-1 Diabetes Mellitus

Arterial hypertension as a consequence of endothelial glycocalyx dysfunction: a modern view of the problem of cardiovascular diseases

Blood pressure management in type 2 diabetes: a review of recent evidence

Pathophysiological and clinical aspects of the circadian rhythm of arterial stiffness in diabetes mellitus: A minireview

Disorders of Blood Pressure Regulation—Role of Catecholamine Biosynthesis, Release, and Metabolism